Open access
Open access
Powered by Google Translator Translator

RCT | Immunogenicity and safety of one-dose human papillomavirus vaccine vs. two or three doses.

29 Sep, 2022 | 13:21h | UTC

Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial – The Lancet Global Health

Invited Commentary: HPV vaccines: when one plus one equals three – The Lancet Global Health

Related:

RCT: Single-dose HPV vaccination found effective among young African women.

Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Opinion: A Single-dose HPV Vaccine Would Have a Big Impact on Cancer Prevention

Another Observational Study Suggests One Dose of HPV Vaccine may be Enough

Another Study Suggesting One Dose of HPV Vaccine may be Effective for Prevention of Cervical Cancer

Comparison of different human papillomavirus (HPV) vaccines and the number of doses administered to prevent HPV-related disease in females and males – Cochrane Library

Large Observational Study Suggests One Dose of HPV Vaccine May Be as Effective as Three

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.